In discussion regarding the new MRI consensus guidelines for patients with MS, Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss key points for their peers and colleagues.
Investigators found that certain underrepresented communities were less likely to be eligible for Alzheimer disease trials after the first screening visit.
These study results highlight the interest in immunosuppressive therapy taken before or during pregnancy and to reduce the risk of relapse during pregnancy and 1 year postpartum.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Raman Malhotra, MD.
Chaired by Brian G. Weinshenker, MD, the presentations also feature Mayo Clinic experts W. Oliver Tobin, MBBCh, BAO, PhD; Jessica Stulc, MD, MPH; and Orhun H. Kantarci, MD. [WATCH TIME: 1 hour, 30 minutes]
Implementing new recommendations for the use of MRI in patients with MS will be a challenge in terms of education and adherence; Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the next steps to increase awareness for both patients and providers.
The position statement considers the diagnosis of dementia, problems in decision making, symptoms and behavioral management, and the relationship between dementia care and society.
Scott D. Newsome, DO, and David Li, MD, FRCPC, discuss the impact of new MRI consensus guidelines for patients with multiple sclerosis.
The observational study, initiated by Centogene in partnership with Alector, aims to identify and explore the frequency of genetic mutations in patients with frontotemporal dementia.
Just as sleep is a necessity each night, it is of further benefit when patients are recovering from injury in the hospital and rehabilitation settings.
A significant proportion of survivors from ICH required substantial continuing care sector resources, namely complex continuing care, long-term care, rehabilitation services, and home care.
Since vaccine administration, the CDC has announced 100 preliminary cases of Guillain-Barré syndrome.
The FDA breakthrough device designation follows a pilot study where patients showed a 44% median reduction in seizures when treated with Neuroelectrics’ transcranial electrical stimulation platform.
The founder and chief scientific officer of Neurolutions discussed complexities within the system to integrate new stroke rehab devices.
Invalid and valid performers did not differ regarding demographic, patient-reported, and disease-related outcomes.
Experts continue to explore connections between sleep health and neurological disorders, as well as technology for measuring patients’ sleep.
The chief medical officer of Scholar Rock described how the investigational apitegromab aims to fill some of the current unmet needs for patients with spinal muscular atrophy.
The data suggest that women considered at high relapse risk or with poor prognostic factors benefit peripregnancy from high-efficacy therapy continuation.
Lucie Barateau, MD, assistant professor of neurology, Hôpital Gui De Chauliac, offered insight on the usefulness of the newly developed pediatric narcolepsy type 1 severity scale.
The associate professor of neurology at Washington University in St. Louis discussed how developing programs focused on sleep health are a step to increasing awareness and understanding its integral role in overall well-being.
Episode 12 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; Clifton L. Gooch, MD, of the University of South Florida; and Sharyl Martini, MD, PhD, of the VHA and Baylor College of Medicine. [WATCH TIME: 4 minutes]
Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.
Raman Malhotra, MD, associate professor of neurology at Washington University in St. Louis, commented on the importance of sleep education, particularly for younger generations.
Efficacy results from a 109-week interim analysis showed improvement for patients treated with viltolarsen when compared to the matched DMD historical control group.
The chief medical officer of Scholar Rock detailed the additive benefits apitegromab has in treating SMA when used with previously approved nusinersen.
ATH-1017, an investigational agent designed to focus on network recovery and synaptic signal transition in the brain, will be evaluated in patients on cognition, global, and functional assessments.
Raman Malhotra, MD, associate professor of neurology at Washington University in St. Louis, discussed the importance inquiring about patients’ sleep, as well as the dangers of insufficient sleep.
Here's what is coming soon to NeurologyLive.
Total lesion volume and index lesion-related severity correlated with EDSS scores and cognitive performance, while volumetric cortical and subcortical gray matter correlated less strongly.
